Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

>

Of 18 evaluable patients who received the every-four-week FOLPI regimen, 67 percent achieved disease control (partial response and stable disease). Of 55 evaluable patients who received the every-two-week FOLPI regimen, 75 percent achieved disease control.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that it has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest manageable hematologic adverse events with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 2 clinical trial in CRC, Poniard is currently evaluating the efficacy and safety of picoplatin in small cell lung cancer in a pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with castration-resistant (or hormone-refractory) prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information p
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Just released this month on Amazon and ... Barbara Roche: “Commit to Confidence: 30 Strategies to Help ... tips and quotes from the fields of psychology and business, ... that readers can do on their own or with a ... and professional goals. , “My book is a ...
(Date:5/22/2013)... Cambridge Semantics was one of just ... Day” on Capitol Hill, hosted by The Data ... others to showcase how innovative data management applications can address ... (DATA Act). , Originally introduced in 2011 by Committee ... Mark Warner (D-VA ), the DATA Act is ...
(Date:5/22/2013)...  Superior Controls, Inc. has been named "Manufacturing/Technology ... Magazine.  For the past 22 years, the magazine ... with extraordinary business and civic excellence. ... said Rick Pierro , President ... award is a reflection of Superior Controls, continuing ...
(Date:5/22/2013)... 2013 AudioNotch is ... tinnitus treatment. AudioNotch is pleased to announce a ... locations in both British Columbia and Alberta, Destination ... hearing services. AudioNotch's tinnitus treatment program is now ... a Destination Hearing clinic, patients have the detection ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2
... ATLANTA, Sept. 22 The International Executive Search Federation ... joined its global network. IESF is the world,s largest retained ... Associates (SRA) as one of its global partners. The extensive ... throughout the USA will considerably enhance IESF,s presence in the ...
... KVISTGAARD, Denmark, September 22 Bavarian,Nordic A/S ... European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO ... data from a Phase II double-blind, prospective randomized,placebo-controlled study ... Dr. Wayne Godfrey, Senior Medical Director, BN,ImmunoTherapeutics. , ...
... BETHESDA, Md., Sept. 22 Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, today ... Vice President and Chief Medical Officer effective November 1, 2009. ... a board-certified clinical oncologist and has more than 20 years ...
Cached Biology Technology:Sanford Rose Associates Joins the International Executive Search Federation 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 2Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 4
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
(Date:5/22/2013)... Bethesda, Md. (May 22, 2013)The omega 3 fatty acids ... against cardiovascular diseaseso much so that the American Heart ... fish a week, particularly fatty varieties rich in omega ... remains a mystery. In a new study, scientists led ... light on this phenomenon by providing evidence that fish ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... AIDS vaccine tested in people, but found to be ... slipped past. The findings suggest new ideas for developing ... 27 in Nature Medicine . This is ... HIV-1 infection exert selective pressure on the virus. "Selective ...
... Methane is an extremely potent greenhouse gas. Wetlands, ... are all natural sources of atmospheric methane; however, the ... human-related activities. These activities include: such as fossil fuel ... release of methane into the atmosphere by cattle and ...
... for professionals in biomedical and health informatics, sent comments ... Health Information Technology (DHHS/ ONCHIT), which has actively supported ... health records (EHRs) over the last year, and which ... the continuation of support for achieving meaningful use of ...
Cached Biology News:For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus 2For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus 3Measuring methane 2AMIA on meaningful use: Invest in people and technology 2
... the formation of phosphodiester bonds in the ... 3' hydroxyl and 5' phosphate termini. The ... which can be performed in 5 minutes ... for this enzyme. A T4 DNA ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
Biology Products: